EXACT Sciences Corporation Stock News

The new year brings a clean slate heading into the fourth-quarter earnings season. Companies can usually gauge if their previous forecasts were in line or need to be adjusted to warn or prepare invest

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

Jared Holz, Mizuho healthcare sector specialist, joins 'The Exchange' to discuss the 2024 outlook for health care, which stocks to buy in the new year, and more.

Mainz Biomed N.V. MYNZ recently released the results of its ColoFuture study in the American healthcare market.

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.

Healthcare stocks rarely outperform the S&P 500 over long periods. Exact Sciences and Vertex Pharmaceuticals have been two of the rare exceptions over the prior 10 years.

In the rapidly evolving healthcare sector, the idea of personalized medicine stocks stands out, revolutionizing patient care by tailoring treatments with their individual genetic profiles. These stock

If you're searching for digital health stocks to add to your portfolio, look no further. Technological innovation is leading to the increased digitalization and personalization of healthcare.

In a world in constant evolution and growth, more and more companies are needed that are committed to development and research in the health area. These biotech companies are not only doing the job, b

We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

Multi-billionaire investor Ken Fisher wrote recently that the stocks of relatively small companies tend to be very unpopular with the Street during the early phase of bull markets. Therefore, Fisher's

From a technical perspective, Exact Sciences (EXAS) is looking like an interesting pick, as it just reached a key level of support. EXAS recently overtook the 20-day moving average, and this suggests

Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.

MADISON, Wis. , Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate

Many investors are probably upset that the yields of the 10-year treasury bonds are trading around 5%. It's true that higher bond yields do increases companies' borrowing costs and make stocks less at